Disease · MONDO_0006624
Comparisons in its trials80
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 80
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Male vs Female: Risk Factors for the Proportion of Responders of Tolterodine-Gender | 2,745 of 3,394 | 3,791 of 4,386 | 7,780 | NCT01488578 | Trial comparisons |
| With Non-drug Therapies vs Without Non-drug Therapies: Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies | 317 of 360 | 6,219 of 7,420 | 7,780 | NCT01488578 | Trial comparisons |
| With Concomitant Drugs vs Without Concomitant Drugs: Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs | 3,483 of 4,214 | 3,053 of 3,566 | 7,780 | NCT01488578 | Trial comparisons |
| With Complications vs Without Complications: Risk Factors for the Proportion of Responders of Tolterodine-Complications | 3,960 of 4,806 | 2,576 of 2,974 | 7,780 | NCT01488578 | Trial comparisons |
| <65 Years vs >=65 Years: Risk Factors for the Proportion of Responders of Tolterodine-Age | 2,060 of 2,379 | 4,476 of 5,401 | 7,780 | NCT01488578 | Trial comparisons |
| With Previous Treatment vs Without Previous Treatment: Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment | 698 of 943 | 5,753 of 6,736 | 7,679 | NCT01488578 | Trial comparisons |
| With Urinary Urgency vs Without Urinary Urgency: Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency | 5,529 of 6,521 | 829 of 1,043 | 7,564 | NCT01488578 | Trial comparisons |
| With BPH vs Without BPH: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy | 319 of 2,203 | 130 of 1,855 | 4,058 | NCT01488578 | Trial comparisons |
| Mirabegron 50 mg vs Solifenacin 5 mg: serious adverse events | 14 of 936 | 13 of 934 | 1,870 | NCT01638000 | Trial comparisons |
| Vibegron 75 Milligrams (mg) Once Daily (QD) vs Placebo: deaths from any cause | 0 of 553 | 0 of 551 | 1,104 | NCT03902080 | Trial comparisons |
| Vibegron 75 Milligrams (mg) Once Daily (QD) vs Placebo: serious adverse events | 24 of 553 | 16 of 551 | 1,104 | NCT03902080 | Trial comparisons |
| Fesoterodine vs Placebo: serious adverse events | 5 of 463 | 9 of 474 | 937 | NCT00911937 | Trial comparisons |
| Mirabegron vs Placebo: deaths from any cause | 0 of 445 | 0 of 442 | 887 | NCT02216214 | Trial comparisons |
| Mirabegron vs Placebo: serious adverse events | 15 of 445 | 12 of 442 | 887 | NCT02216214 | Trial comparisons |
| Oxybutynin Topical Gel vs Placebo Topical Gel: serious adverse events | 7 of 389 | 10 of 400 | 789 | NCT00350636 | Trial comparisons |
| Solifenacin Succinate vs Placebo: serious adverse events | 3 of 386 | 6 of 382 | 768 | NCT00573508 | Trial comparisons |
| Mirabegron vs Tolterodine ER: serious adverse events | 3 of 319 | 8 of 325 | 644 | NCT02138747 | Trial comparisons |
| onabotulinumtoxinA vs Placebo/onabotulinumtoxinA: serious adverse events | 18 of 278 | 16 of 272 | 550 | NCT00910845 | Trial comparisons |
| onabotulinumtoxinA vs Placebo/onabotulinumtoxinA: serious adverse events | 17 of 274 | 15 of 270 | 544 | NCT00910520 | Trial comparisons |
| Overall Vibegron 75 mg vs Overall Tolterodine ER 4 mg: deaths from any cause | 1 of 273 | 0 of 232 | 505 | NCT03583372 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006624/comparisons